To investigate the potential of the PPARγ partial agonist MEKT-21 as an anti-scirrhous gastric cancer agent, we compared the apoptosis-inducing effects of MEKT-21 and MO-4R, together with the human PPARγ full agonist, troglitazone, on the human scirrhous gastric cancer cell line OCUM-2MD3 [60]. This evidence concerns the gene PPARG and gastric cancer.